A5033280951- CAR-T cell therapy research
- Sarcoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Virus-based gene therapy research
- Veterinary Oncology Research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- Cell Adhesion Molecules Research
- Lymphoma Diagnosis and Treatment
- Renal cell carcinoma treatment
- Renal Transplantation Outcomes and Treatments
- Organ and Tissue Transplantation Research
- Cytomegalovirus and herpesvirus research
- Vascular Tumors and Angiosarcomas
- Cancer Immunotherapy and Biomarkers
- Biomedical Ethics and Regulation
- Acute Myeloid Leukemia Research
- Viral Infectious Diseases and Gene Expression in Insects
- Colorectal and Anal Carcinomas
- Viral Infections and Immunology Research
- Organ Transplantation Techniques and Outcomes
Fred Hutch Cancer Center
2019-2024
Clinical Research Management
2021
Abstract Interferon-γ (IFNγ) has been studied as a cancer treatment with limited evidence of clinical benefit. However, it could play role in immunotherapy combination treatments. Despite high expression immunogenic cancer–testis antigens, synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) have cold tumor microenvironment (TME), few infiltrating T cells low major histocompatibility complex class I (MHC-I). We hypothesized that IFNγ drive inflammation TME, facilitating further...
<h3>Importance</h3> Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in soft-tissue sarcoma over doxorubicin monotherapy, each has fallen short of demonstrating outcomes. <h3>Objective</h3> To evaluate the safety efficacy combination pembrolizumab advanced, anthracycline-naive <h3>Design, Setting, Participants</h3> This nonrandomized clinical trial used a...
Metastatic soft tissue sarcomas (STSs) have limited systemic therapy options, and immunomodulation has not yet meaningfully improved outcomes. Intratumoral (IT) injection of the toll-like receptor 4 (TLR4) agonist glycopyranosyl lipid A in stable-emulsion formulation (GLA-SE) been studied as immunotherapy other contexts.To evaluate safety, efficacy, immunomodulatory effects IT GLA-SE with concurrent radiotherapy patients metastatic STS injectable lesions.This phase 1 nonrandomized controlled...
Abstract Purpose: Leiomyosarcoma and liposarcoma frequently express PD-L1 but are generally resistant to PD-1/PD-L1 inhibition (immune checkpoint inhibitor). Trabectedin is FDA approved for leiomyosarcoma liposarcoma. This study aimed evaluate the safety efficacy of trabectedin with anti–PD-L1 antibody avelumab in patients advanced Patients Methods: A single-arm, open-label, Phase 1/2 tested The phase I portion evaluated feasibility (1, 1.2, 1.5 mg/m2) at standard dosing. Primary endpoint II...
Abstract One obstacle for human solid tumor immunotherapy research is the lack of clinically relevant animal models. In this study, we sought to establish a chimeric antigen receptor (CAR) T-cell treatment model naturally occurring canine sarcomas as CAR therapy. Canine CARs specific B7-H3 were constructed using single-chain variable fragment derived from B7-H3–specific antibody MGA271, which confirmed be cross-reactive with B7-H3. After refining activation, transduction, and expansion...
Background Myelodysplastic syndromes (MDS) arise from somatic mutations acquired in hematopoietic stem and progenitor cells, causing cytopenias predisposing to transformation into secondary acute myeloid leukemia (sAML). Recurrent spliceosome genes, including U2AF1 , are attractive therapeutic targets as they prevalent MDS sAML, early neoplastic generally absent normal cells. sAML susceptible T cell-mediated killing, thus engineered T-cell immunotherapies hold promise for their treatment. We...
Background Synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) are ideal solid tumors for the development of adoptive cellular therapy (ACT) targeting NY-ESO-1, as a high frequency homogeneously express this cancer-testes antigen. Data from early phase clinical trials have shown antitumor activity after transfer NY-ESO-1–specific T cells. In these studies, persistence NY-ESO-1 specific cells is highly correlated with response to ACT, but patients often continue detectable...
Adoptive cellular therapy (ACT) is a promising treatment for synovial sarcoma (SS) with reported response rates of over 50%. However, more work needed to obtain deeper and durable responses. SS has 'cold' tumor immune microenvironment low levels major histocompatibility complex (MHC) expression few T-cell infiltrates, which could represent barrier toward successful ACT. We previously demonstrated that both MHC infiltration can be increased using systemic interferon gamma (IFN-γ), improve the...
<h3>Background</h3> Chimeric antigen receptor (CAR) T cell therapy has transformed for hematological malignancies but not yet been established as standard of care any solid tumors. One obstacle human tumor immunotherapy research is the lack clinically relevant, immunocompetent animal models. In this study, we sought to establish CAR cells naturally occurring canine sarcomas in client owned animals a model therapy. <h3>Methods</h3> Archived FFPE, freshly isolated samples well lines were...
Supplementary Data from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
<div>AbstractPurpose:<p>Leiomyosarcoma and liposarcoma frequently express PD-L1 but are generally resistant to PD-1/PD-L1 inhibition (immune checkpoint inhibitor). Trabectedin is FDA approved for leiomyosarcoma liposarcoma. This study aimed evaluate the safety efficacy of trabectedin with anti–PD-L1 antibody avelumab in patients advanced liposarcoma.</p>Patients Methods:<p>A single-arm, open-label, Phase 1/2 tested The phase I portion evaluated feasibility (1, 1.2,...
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Data from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma
Supplementary Figure from A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma Leiomyosarcoma